Axel Heidenreich | AMiner学者主页

全面呈现 [Axel Heidenreich] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

暂无数据

论文（45）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1Clinical relevance of the MDR-1 expression in the testicular tumour

M. Seger,P. Olbert,A. Hegele,L. Konrad,A. Heidenreich, R. Hofmann

2008ONKOLOGIE（2008）

引用

AI阅读

2Contents Vol. 76, 2006

Massimo Lazzeri,A.K. Taghizadeh, Abdolhossein Madani,Paul R. Gard,C.-Y. Li, Paal Thomas,S.P. Denyer,Seung-June On,Ja Hyeon Ku,Mehdi Salehipour,Abdolaziz Khezri,Valiallah Azizi,

2006Urologia internationalis（2006）

引用

AI阅读

3Subject Index Vol. 76, 2006

Massimo Lazzeri,Arash Taghizadeh, Ahmad Madani,P.R. Gard,Chung‐Yi Li, Paul J. Thomas,S.P. Denyer,Seung-June On, Hyeong Dong Yuk,Mehdi Salehipour,Abdolaziz Khezri,Valiallah Azizi,

2006Urologia Internationalis（2006）引用：1

引用

AI阅读

4Klinische Signifikanz Eines PSA Flare Phänomens Bei Patienten Mit Hormonrefraktärem Prostatakarzinom Unter Docetaxel – Basierter Therapie

P Olbert,AJ Schrader,S Sevinc,A Heidenreich,R Hofmann

Bis vor kurzem galt die zytotoxische Chemotherapie in der Behandlung des fortgeschrittenen Prostatakarzinoms als ineffektiv. Neuere Substanzen lassen nun jedoch verbessertes klinisches Potential erwarten. Insbesondere Docetaxel erbrachte sowohl als Monotherapeutikum als auch in Kombination mit anderen Medikamenten vielversprechende Ergebnisse in der Behandlung des hormonrefraktären Prostatakarzinoms (HRPCA). Das PSA Flare-Phänomen ist in der androgenablativen Therapie des fortgeschrittenen Prostatakarzinoms mit LHRH-Analoga gut bekannt; kürzlich wurde es auch im Rahmen der palliativen Chemotherapie des HRPCA beschrieben. Ziel unserer Studie war es, Häufigkeit und klinische Signifikanz eines solchen PSA Flare unter Docetaxel basierter Therapie bei HRPCA – Patienten zu definieren.

2006Aktuelle Urologie（2006）引用：2

引用

AI阅读

5TABLES FOR PREDICTING POST-PROSTATECTOMY INCONTINENCE (PPI)

S. Wille,C. Ohlmann,A. Heidenreich, R. Hofmann,U. Engelmann

2006European Urology Supplements（2006）

引用

AI阅读

6922Thalidomide / Interleukin-2 in Metastatic Kidney Cancer Refractory to Chemoimmunotherapy

Schrader A.J.,Heidenreich A.,Hegele A.,Olbert P.,Varga Z., Ohlmann C.H.,Von Knobloch R., Hoffmann R.

2005European Urology Supplements（2005）

引用

AI阅读

7390Investigation of Microdeletions of Testicular Determining Genloci SRY and AZF on Chromosome YQ in Patients with Undescended Testis

Elert A., Ohlmann C.H.,Heidenreich A.,Hofmann R.

2005European Urology Supplements（2005）

引用

AI阅读

8981Psa-Flare Up in Docetaxel Therapy of Hrpc: Incidence and Clinical Impact?

Olbert P.,Schrader A.,Hegele A.,Varga Z.,Heidenreich A., Hofmann R.

2005European Urology Supplements（2005）

引用

AI阅读

9167: Impact of Electrical Stimulation or Biofeedback on Quality of Life after Radical Prostatectomy: Results of a Prospective Randomized Trial

S Wille,A Sobottka,P Olbert,A Heidenreich,R Hofmann

You have accessJournal of UrologyDiscussed Poster, Saturday, May 8, 2004, 1:00 - 5:00 pm1 Apr 2004167: Impact of Electrical Stimulation or Biofeedback on Quality of Life After Radical Prostatectomy: Results of a Prospective Randomized Trial Sebastian Wille, Axel Sobottka, Peter Olben, Axel Heidenreich, and Rainer Hofmann Sebastian WilleSebastian Wille , Axel SobottkaAxel Sobottka , Peter OlbenPeter Olben , Axel HeidenreichAxel Heidenreich , and Rainer HofmannRainer Hofmann View All Author Informationhttps://doi.org/10.1016/S0022-5347(18)37429-9AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "167: Impact of Electrical Stimulation or Biofeedback on Quality of Life After Radical Prostatectomy: Results of a Prospective Randomized Trial." The Journal of Urology, 171(4S), pp. 44–45 © 2016 by American Urological AssociationFiguresReferencesRelatedDetails Volume 171Issue 4SApril 2004Page: 44-45 Advertisement Copyright & Permissions© 2016 by American Urological AssociationMetricsAuthor Information Sebastian Wille More articles by this author Axel Sobottka More articles by this author Peter Olben More articles by this author Axel Heidenreich More articles by this author Rainer Hofmann More articles by this author Expand All Advertisement PDF downloadLoading ...

2004The Journal of Urology（2004）引用：2

引用

AI阅读

10613 Docetaxel (DOC) and Mitoxantrone (MIT) in the Management of Hormone Refractory Prostate Cancer (HRPCA)

Heidenreich A.,Schrader A.,Olbert P.,Ohlmann C., Hegel A., Hofmann R.

2004European Urology Supplements（2004）

引用

AI阅读

1154 Extended Pelvic Lymphadenectomy in Men Undergoing Radical Retro Pubic Prostatectomy (RRP) — an Update on > 300 Cases

A Heidenreich,R von Knobloch,Z Varga,R Hofmann

2004European Urology Supplements（2004）引用：4

引用

AI阅读

12706 Cellular Fibronectin Plasma Levels in Localized and Metastatic Renal Cell Carcinoma

Hegele A.,Heidenreich A.,Varga Z.,Olbert P.,Kropf J.,Von Knobloch R., Hofmann R.

2004European Urology Supplements（2004）

引用

AI阅读

13708 Dysregulation of Cellular Retinoic Acid-Binding Protein (CRABP)-1 in Renal Cell Carcinoma

Schrader A.J.,Hansen W.,Pfoertner S.,Goelden U.,Buer J.,Heidenreich A.,Hofmann R.

2004European Urology Supplements（2004）

引用

AI阅读

14194 Sacral Colpopexy with Concomitant Burch Colposuspension

Wille S.,Varga Z.,Hegele A.,Heidenreich A., Hofmann R.

2004European Urology Supplements（2004）

引用

AI阅读

15314: Gemcitabine Based Chemotherapy of Advanced Bladder Cancer in Elderly Patients-Investigations about the Influence of Age and Comorbidity on Therapy Caused Morbidity and Mortality

A Elert,C Ohlmann,AJ Schrader,R Hofmann,A Heidenreich

You have accessJournal of UrologyDiscussed Poster, Sunday, May 9, 2004, 8:00 am - 12:00 pm1 Apr 2004314: Gemcitabine Based Chemotherapy of Advanced Bladder Cancer in Elderly Patients-Investigations About the Influence of Age and Comorbidity on Therapy Caused Morbidity and Mortality Achim Elert, Carsten Ohlmann, Andres J. Schrader, Rainer Hofmann, and Axel Heidenreich Achim ElertAchim Elert More articles by this author , Carsten OhlmannCarsten Ohlmann More articles by this author , Andres J. SchraderAndres J. Schrader More articles by this author , Rainer HofmannRainer Hofmann More articles by this author , and Axel HeidenreichAxel Heidenreich More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(18)37576-1AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "314: Gemcitabine Based Chemotherapy of Advanced Bladder Cancer in Elderly Patients-Investigations About the Influence of Age and Comorbidity on Therapy Caused Morbidity and Mortality." The Journal of Urology, 171(4S), pp. 82–83 © 2016 by American Urological AssociationFiguresReferencesRelatedDetails Volume 171Issue 4SApril 2004Page: 82-83 Advertisement Copyright & Permissions© 2016 by American Urological AssociationMetricsAuthor Information Achim Elert More articles by this author Carsten Ohlmann More articles by this author Andres J. Schrader More articles by this author Rainer Hofmann More articles by this author Axel Heidenreich More articles by this author Expand All Advertisement PDF downloadLoading ...

2004JOURNAL OF UROLOGY（2004）

引用

AI阅读

16649 Do Evidence Based Guidelines Influence the Indivisual Therapeutic Approach in Patients with Testicular Cancer?